Multiple system atrophy-derived α-synuclein fibrils are more potent and display oligodendrocyte cell tropism compared to Parkinson's disease-derived fibrils.
Aug 2026· Neurobiology of Disease· pp.
107575
· 0 citations· 63 references
Medicine
TL;DR
Interestingly, amplified material from MSA brains induced significantly more oligodendroglial pSyn aggregates than amplified material from PD brains, and mice injected with the fibril polymorph, showed mild changes in microglial reactivity.
Abstract
Multiple System Atrophy (MSA) and Parkinson's Disease (PD) are neurodegenerative diseases characterized by abundant α-synuclein (αSyn) aggregation in the brain. Compared to PD patients, MSA patients have more widespread neurodegeneration and a more aggressive disease course. PD-related αSyn pathology is primarily neuronal, whereas MSA brains characteristically display oligodendroglial inclusions. The strain hypothesis poses that polymorphisms of the αSyn aggregates, so-called strains, may explain disease heterogeneity. The present study investigates the differential properties of αSyn fibrils derived from MSA and PD patients' brains using the protein misfolding cyclic amplification (PMCA) method in cultured neurons and in vivo. MSA- and PD-derived αSyn species were administered to primary murine neuronal cell cultures or injected intrastriatally into wildtype mice, along with de novo generated αSyn fibrils of the ribbon and fibril types. The potency to induce phosphorylated αSyn (pSyn) pathology, microglial reactivity, and the extent of oligodendroglial pSyn pathology were compared among the different seeding materials using immunohistochemical and immunofluorescent approaches. In summary, the various seeding materials induced pSyn pathology of distinguishable potency and morphology. PMCA-derived material from MSA brains and the fibril polymorph induced more pSyn pathology in both neuronal cultures and in mice compared to PMCA-derived material from PD brains and the ribbon polymorph. Interestingly, amplified material from MSA brains induced significantly more oligodendroglial pSyn aggregates than amplified material from PD brains. Additionally, mice injected with the fibril polymorph, showed mild changes in microglial reactivity. Our findings suggest specific properties of the MSA- and PD-derived fibrils, and overall support the strain hypothesis.
PrPC expression levels are identified as an important modulator of nigrostriatal vulnerability and neuroinflammatory phenotype in response to αSynO, supporting the hypothesis that PrPC contributes to αSynO-mediated pathogenic mechanisms.
Flavio de Souza Júnyor, F. Leser, Sarah de Souza Albuquerque et al.· Frontiers in Neuroscience· 0 citations
A model in which α-syn oligomer spreading, amplified by aging, simultaneously disrupts the astrocyte–glutamatergic neuron axis and drives microglia into a senescent DAM-like state is proposed, and candidate gene sets for both processes are provided for further investigation of glial dysfunction in PD.
Overexpression of Kcnn1, a potassium channel subunit, appears to be neuroprotective in Parkinson’s Disease, and its action may have therapeutic implications.
Maria Nagy, W. Fenton, A. Horwich· Proceedings of the National...· 0 citations
A genetically controlled in vivo model of LBD-like mixed proteinopathy recapitulating αSyn aggregation, tau hyperphosphorylation, Aβ accumulation, neurodegeneration, and behavioral decline is established and supports a mechanistic link between AIMP2-enhanced αSyn toxicity and secondary proteinopathies.
Doeun Kim, Hee-Tae Kim, Ji Hun Kim et al.· Cell Death & Disease· 0 citations
Abstract Conformationally distinct “strains” of α‐synuclein aggregates are believed to contribute to the clinical and pathological diversity observed among synucleinopathies such as multiple system atrophy (MSA) and Parkinson's disease. Cases of MSA can be classified into two distinct subtypes: the cerebellar variant,...
Heather H. C. Lau, N. R. G. Silver, Surabhi Mehra et al.· Brain Pathology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.